-
公开(公告)号：WO2008067164A2
公开(公告)日：2008-06-05
申请号：PCT/US2007/084617
申请日：2007-11-14
Applicant: ABBOTT LABORATORIES , BERNDL, Gunther , ROSENBERG, Joerg , FASTNACHT, Katja , LIEPOLD, Bernd , BREITENBACH, Joerg , JUNG, Tina , ROTH, Wolfgang , MORRIS, John , KLEIN, Cheri, E. , CAI, Yan , ALANI, Laman , GHOSH, Soumojeet
Inventor： BERNDL, Gunther , ROSENBERG, Joerg , FASTNACHT, Katja , LIEPOLD, Bernd , BREITENBACH, Joerg , JUNG, Tina , ROTH, Wolfgang , MORRIS, John , KLEIN, Cheri, E. , CAI, Yan , ALANI, Laman , GHOSH, Soumojeet
IPC: A61K9/20 , A61K31/427
CPC classification number: A61K31/427 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2095
Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.
Abstract translation: 本发明的特征在于包含利托那韦的固体药物剂型。 作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如 作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。 优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。
-
公开(公告)号：WO2012061780A1
公开(公告)日：2012-05-10
申请号：PCT/US2011/059458
申请日：2011-11-04
Applicant: ABBOTT GMBH & CO. KG , ABBOTT LABORATORIES , GHOSH, Soumojeet , LEFEBVRE, Didier , WIESNER, Bryan , BREITENBACH, Joerg , KESSLER, Thomas
Inventor： GHOSH, Soumojeet , LEFEBVRE, Didier , WIESNER, Bryan , BREITENBACH, Joerg , KESSLER, Thomas
IPC: A61J3/06
CPC classification number: A61K9/2095 , A61J3/06 , A61J3/10
Abstract: The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.
Abstract translation: 本发明涉及一种整体式片剂的制造方法。 该方法使用至少含有活性剂和至少一种热塑性粘合剂的熔融加工组合物。 本发明还涉及一种用于对熔融加工的组合物的预成形体的带进行切割和去屑的方法，其中预成形体通过闪光相互连接。
-
公开(公告)号：WO2005039551A2
公开(公告)日：2005-05-06
申请号：PCT/US2004/027401
申请日：2004-08-23
Applicant: ABBOTT LABORATORIES , ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , DERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
Inventor： ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , DERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
IPC: A61K31/00
CPC classification number: A61K31/425 , A61K9/146 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2866
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Abstract translation: 公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。 特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 C。 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。
-
公开(公告)号：WO2012061779A1
公开(公告)日：2012-05-10
申请号：PCT/US2011/059456
申请日：2011-11-04
Applicant: ABBOTT GMBH & CO. KG , ABBOTT LABORATORIES , GHOSH, Soumojeet , LEFEBVRE, Didier , WIESNER, Bryan , BREITENBACH, Joerg , KESSLER, Thomas
Inventor： GHOSH, Soumojeet , LEFEBVRE, Didier , WIESNER, Bryan , BREITENBACH, Joerg , KESSLER, Thomas
CPC classification number: A61K9/2077 , A61K9/146 , A61K9/2054
Abstract: In one embodiment, the present invention relates to abuse-deterrent drug formulations comprise a plurality of discrete domains uniformly dispersed in a pharmaceutically acceptable matrix, wherein said domains have high fracture toughness and comprise at least one polymer and at least one abuse-relevant drug. In another embodiment, the present invention relates to a formulation comprising a plurality of discrete mechanically reinforcing particles uniformly dispersed in a pharmaceutically acceptable matrix, wherein said matrix has high fracture toughness and comprises at least one polymer and at least one active agent, at least one abuse-relevant drug or a combination of at least one active agent and at least one abuse-relevant drug.
Abstract translation: 在一个实施方案中，本发明涉及滥用 - 威慑药物制剂包含均匀分散在药学上可接受的基质中的多个离散区域，其中所述区域具有高断裂韧性并且包含至少一种聚合物和至少一种滥用相关药物。 在另一个实施方案中，本发明涉及包含均匀分散在药学上可接受的基质中的多个离散的机械增强颗粒的制剂，其中所述基质具有高断裂韧性，并且包含至少一种聚合物和至少一种活性剂，至少一种 滥用相关药物或至少一种活性剂和至少一种滥用相关药物的组合。
-
公开(公告)号：WO2006091529A2
公开(公告)日：2006-08-31
申请号：PCT/US2006/005944
申请日：2006-02-21
Applicant: ABBOTT LABORATORIES , ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , BERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
Inventor： ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , BERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
IPC: A61K31/513 , A61K31/426 , A61K9/20 , A61K9/28
CPC classification number: A61K9/1694 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/204 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/00 , A61K31/426 , A61K31/427 , A61K31/513 , A61K47/32 , A61K2300/00
Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
Abstract translation: 本发明提供药物剂型制剂，更具体地说，涉及包含HIV蛋白酶抑制剂的药物剂型。
-
Patent Agency Ranking
公开(公告)号：WO1998022106A1
公开(公告)日：1998-05-28
申请号：PCT/US1997020794
申请日：1997-11-12
Applicant: ABBOTT LABORATORIES
Inventor： ABBOTT LABORATORIES , LIPARI, John , AL-RAZZAK, Laman, A. , GHOSH, Soumojeet , GAO, Rong , KAUL, Dilip
IPC: A61K31/425
CPC classification number: A61K38/55 , A61K9/4858 , A61K31/341 , A61K31/426 , A61K31/4433 , A61K31/47 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/513 , A61K31/5375 , A61K31/551 , A61K38/05 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , Y02A50/465
Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelating capsules or soft elastic capsules (SEC).
Abstract translation: 对于作为HIV蛋白酶抑制剂的化合物，公开了提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 组合物可任选地包封在硬胶囊或软弹性胶囊（SEC）中。
-
公开(公告)号：EP1663183B1
公开(公告)日：2011-07-13
申请号：EP04816820.7
申请日：2004-08-23
Applicant: ABBOTT LABORATORIES
Inventor： ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , DERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
IPC: A61K9/14 , A61K31/425 , A61K9/20
CPC classification number: A61K31/425 , A61K9/146 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2866
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
-
公开(公告)号：EP2112925A2
公开(公告)日：2009-11-04
申请号：EP07871461.5
申请日：2007-11-14
Applicant: Abbott Laboratories
Inventor： BERNDL, Gunther , ROSENBERG, Joerg , FASTNACHT, Katja , LIEPOLD, Bernd , BREITENBACH, Joerg , JUNG, Tina , ROTH, Wolfgang , MORRIS, John , KLEIN, Cheri E. , CAI, Yan , ALANI, Laman , GHOSH, Soumojeet
CPC classification number: A61K31/427 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2095
Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.
-
公开(公告)号：EP1248600A1
公开(公告)日：2002-10-16
申请号：EP00982360.0
申请日：2000-12-01
Applicant: ABBOTT LABORATORIES
Inventor： ALANI, Laman , GHOSH, Soumojeet
CPC classification number: A61K9/4858 , A61K47/10 , A61K47/12 , Y02A50/465
Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
-
公开(公告)号：EP1663183B9
公开(公告)日：2012-06-13
申请号：EP04816820.7
申请日：2004-08-23
Applicant: ABBOTT LABORATORIES
Inventor： ROSENBERG, Jöerg , REINHOLD, Ulrich , LIEPOLD, Bernd , DERNDL, Gunther , BREITENBACH, Jörg , ALANI, Laman , GHOSH, Soumojeet
IPC: A61K9/14 , A61K31/425 , A61K9/20
CPC classification number: A61K31/425 , A61K9/146 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2866
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50 °C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.032 seconds)
